CTIS2022-502010-85-00招募中1 期
An open-label, multicenter, Phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor Tuvusertib (M1774) in combination with cemiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-PD-(L)1 and platinum-based therapies (DDRiver NSCLC 322) - MS201924_0022
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Are = 18 years of age at the time of signing the informed consent, Are diagnosed with nsqNSCLC histologically or cytologically confirmed, Radiologically confirmed/documented disease progression during or after the following systemic therapies (all required): •a.At most, 1 line of anti-PD-(L)1 therapy for locally advanced or metastatic disease. Note 1: Rechallenge with the same anti-PD-(L)1 for disease considered sensitive to anti-PD-(L)1 therapy (e.g. after a treatment break) is considered 1 line. Note 2: this includes (neo)adjuvant anti-PD-(L)1 therapy for locally advanced disease, provided disease progression occurs within 16 weeks of the last dose of anti-PD-(L)1 therapy. •b.Platinum-based therapy for locally advanced or metastatic disease, given in combination or sequentially with anti-PD-(L)1 therapy. Participants who received (neo)adjuvant platinum-based therapy meet this criterion if disease progression occurred within 6 months from the last dose that the participant received that therapy. No additional cytotoxic therapies after progression on platinum-based therapy are allowed •c.Prior best overall response of stable disease or better with anti-PD-(L)1 therapy •d. Disease progression must have occurred while the participant has been receiving anti-PD-(L)1 therapy or within 16 weeks of the last dose of anti-PD-(L)1 therapy, Measurable disease per RECIST v1.1, as assessed by the Investigator, ECOG PS 0 or 1, Adequate hematological, hepatic and renal function as defined in the protocol., Archival FFPE tumor tissue is available or tumor genomic profiling with a NGS based test performed in a certified laboratory and PD-L1 status as determined by an assay of appropriate regulatory status are required., Phase 2a part only: central liquid biopsy analysis of tumor molecular alterations with an assay with appropriate regulatory status. Participants will be allocated to Stratum A, B and C as defined in the protocol., Other protocol defined inclusion criteria could apply
排除标准
- •Participants with tumors harboring actionable EGFR or ALK genomic aberrations. Participants with tumors with other actionable aberrations are eligible and allowed to have received up to 1 line of available targeted therapy, History of additional malignancy within 3 years before the date of enrollment. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor’s Medical Monitor, is considered cured with minimal risk of recurrence within 3 years, Known brain metastases, unless clinically stable, history of (noninfectious) pneumonitis that required systemic corticosteroids or current pneumonitis/interstitial lung disease, Other protocol defined inclusion criteria could apply.
研究者
相似试验
招募中
1 期
M1774 in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)on-Squamous Non-Small Cell Lung CancerJPRN-jRCT2031230332Ishii Kyoko25
已完成
1 期
An Open-label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)JPRN-jRCT2080222039Eli Lilly Japan K.K.
进行中（未招募）
不适用
A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimeEUCTR2009-015628-27-FRovartis Pharma Services AG52
进行中（未招募）
不适用
A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimeEUCTR2009-015628-27-SEovartis Pharma Services AG52
进行中（未招募）
1 期
A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimeEUCTR2009-015628-27-NLovartis Pharma Services AG45